ISO-Certified Industrial Products Distributor & Light Manufacturer, 27-Year Minnesota Business

$4.3M

Revenue

$981K

SDE

4.7x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a 27-year-old (founded 1998) ISO-certified, FDA-registered B2B distributor and light manufacturer of industrial products serving medical, UPS (uninterruptible power supply), military, lighting, and communication applications. Based in the Twin Cities metro of Minnesota, the company has built a reputation on reliability, service, and technical expertise across end markets that are mostly essential and mission-critical. It operates lean out of a leased 6,000 square foot facility with two owner-operators and seven part-time staff split across production and shipping.

The financials tell a clean growth story. Revenue climbed from $3.62M in 2024 to $4.31M in 2025, with cash flow rising from $825K to $981K. Management projects $5.4M revenue and $1.19M earnings in 2026, backed by a stated 26% year-over-year revenue increase for the January through July comparison period. On the trailing 2025 numbers, the $4.6M asking price represents a 4.69x cash flow multiple, plus $175K of inventory sold outside the price.

What makes this notable is the combination of an ISO/FDA compliance moat, diversified essential end markets, and a genuinely small operational footprint throwing off nearly $1M in owner earnings. The FDA registration and ISO certification create real switching friction for medical and defense customers who cannot casually re-qualify a new vendor. For a buyer, the risk is concentrated in the two departing owners who currently run every function of the business.

Why we like it

Earnings quality is strong and improving, with cash flow growing from $825K in 2024 to $981K in 2025 on revenue of $4.31M, a roughly 23% margin. The trailing numbers are actuals, not projections, and the reported 26% year-to-date revenue lift suggests the momentum is real rather than a broker's hockey stick.
The moat is regulatory and reputational. ISO certification plus FDA registration means medical and military customers cannot swap this vendor without re-qualifying a new supplier, a slow and costly process that keeps incumbent relationships sticky even without formal contracts.
End-market diversification lowers cyclicality. Serving medical devices, UPS power backup, military, lighting, and communications spreads demand across sectors that are largely non-discretionary and mission-critical, so a downturn in one vertical is unlikely to gut the whole book.
The operation is remarkably lean and cheap to run. Two owners plus seven part-timers in a 6,000 square foot leased space at under $60K annual rent generates nearly $1M in cash flow, meaning fixed overhead is low and incremental revenue drops efficiently to the bottom line.

How to improve it

Document and de-risk the owner functions immediately. Both owners currently run sourcing, purchasing, inventory, finance, and shipping personally, so the first 90 days must map every process and hire or promote a plant/operations manager to absorb the production-side owner's role before the earnout window closes.
Formalize customer relationships into contracts or blanket POs. Much of the revenue likely runs on repeat orders and relationships rather than agreements, so converting top accounts to annual supply contracts or forecasted blanket purchase orders would create predictability and lift enterprise value at resale.
Add a dedicated outside or inside sales function. The business has grown 26% seemingly on reputation and inbound demand with zero apparent sales team, which means a modest investment in a rep or CRM-driven outreach could accelerate the existing tailwind meaningfully.
Push margin through pricing and vendor terms. With ISO/FDA switching costs protecting the base, test targeted price increases on qualified specialty parts and renegotiate supplier terms on the highest-volume SKUs to expand the already healthy 23% cash flow margin.
Evaluate expanding capacity ahead of the 2026 projection. Management projects $5.4M revenue next year, but the 6,000 square foot leased facility may bottleneck growth, so scope whether additional space or a second shift is needed and model the ROI before signing anything.
Build a proper inventory management system. Inventory sits at $175K and is owner-controlled, so implementing demand forecasting and reorder-point automation would free working capital and reduce reliance on the departing owner's tribal knowledge of stock levels.
Diversify supplier concentration. Light manufacturing plus distribution means sourcing risk matters, so audit single-source vendors on critical components and qualify backups to protect the FDA/ISO product lines from a supply disruption.

Diligence notes

Verify the 2026 projections against actual year-to-date orders. The pitch leans on a $5.4M revenue and $1.19M earnings projection and a 26% growth claim, so pull the January through July P&L, current backlog, and open POs to confirm the trajectory is durable and not a one-time large order.
Quantify customer concentration across the five end markets. A book this size may have a handful of accounts driving most revenue, so obtain a customer-level revenue breakdown for the last three years and understand what percentage comes from the top five clients and whether any are at risk with the owner exit.
Confirm the ISO and FDA certifications transfer cleanly and are current. These credentials are the core moat, so review certificate dates, audit history, any open corrective actions, and whether the registrations attach to the entity or to the departing owners' personal oversight.
Assess the owner-dependency and transition realistically. Both owners run every function and are retiring, so scope the exact length and terms of transition support, the cost to backfill their roles, and whether the seven part-timers are stable, since the deal quality hinges on operational continuity.
Scrutinize the lease and facility runway. The 6,000 square foot lease runs to June 2031 at $4,964 per month, so confirm renewal options, escalation clauses, and whether the space can accommodate the projected 2026 volume without a costly relocation.
Normalize the add-backs behind the $981K cash flow figure. SDE and EBITDA differ ($981K vs $890K), so reconcile owner compensation for two working owners, verify each add-back, and understand what replacement management will actually cost to run the business post-close.

Source

Originally listed on BizBuySell. View original listing →